Stroke-induced Immunodepression in Neurorehabilitation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-01

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The close interconnection between nervous system and the immune system is well known. Brain injuries lead to homeostasis disruption. On the one hand they result in increased brain inflammation contributing to tissue repair, at the expense of a possible extension of tissue damage. On the other hand, they lead to systemic down-regulation of innate and adaptive immunity, determining higher vulnerability to infections, responsible of death and comorbidities in the acute and subacute setting.

Aim of the study was to evaluate the role of immunosuppression in the neurorehabilitation pathway in patients with stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Immune Response to Stroke

NCT05277129

Stroke, Acute Dementia

RECRUITING

Autoimmune Phenomena After Acute Stroke

NCT01082783

Stroke

COMPLETED

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

NCT05982925

Multiple Sclerosis Neuromyelitis Optica Demyelinating Autoimmune Diseases, CNS

ENROLLING_BY_INVITATION

Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease

NCT06224920

Alzheimer Disease Corticobasal Syndrome

COMPLETED

Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation

NCT06551649

Amyotrophic Lateral Sclerosis Multiple Sclerosis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The perfect balance between nervous and immune system could be severely impaired after brain injuries, such as strokes.

In the acute phase, inflammatory mediators are responsible of central nervous system inflammation, associated to tissue repair at the expense of possible secondary brain injury or damage expansions.

In the mean time, activation of hypothalamic-pituitary-adrenal axis and the autonomic nervous system determine downregulation of innate and adaptive immunity, with decreased circulating T cell count and reduced lymphocytic response. The degree of these changes is linked to the severity of brain damage and inevitably lead to higher vulnerability to infections, representing a negative prognostic factor in the acute phase.

Association between immunosuppression and functional outcome in the neurorehabilitation setting are missing.

Aim of this study was to evaluate the role of immunosuppression in the neurorehabilitation journey in patients with stroke.

We analyzed the neutrophil-to-lymphocyte ratio, a useful tool to investigate alterations in both the innate and adaptive immune systems. We correlated it to clinical and neurorehabilitation scales, investigating disability, functional status, as well as gait analysis and occurrence of infectious complications. All outcomes were measured on admission in Neurorehabilitation setting and at hospital discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Lymphopenia Immunosuppression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stroke patients with immunosuppression

Patients with ischemic or hemorrhagic stroke with a neutrophil to lymphocyte ratio \>= 5 at hospital admission

Neurorehabilitation

Intervention Type OTHER

Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)

Stroke patients without immunosuppression

Patients with ischemic or hemorrhagic stroke with a neutrophil to lymphocyte ratio \< 5 at hospital admission

Neurorehabilitation

Intervention Type OTHER

Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neurorehabilitation

Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of first episode of ischemic stroke or primary spontaneous intracerebral haemorrhage (both confirmed by proper neuroimaging)
* admission to the Neurorehabilitation ward within 30 days from the index event

Exclusion Criteria

* medical history of immunodeficiency or immunoproliferative disease
* immunosuppressive or immunomodulating therapy in the year before the index event
* systemic steroids in the six months before the index event
* Glasgow Coma Scale \< 8 at hospital admission
* other diagnosis of neurological diseases
* missing clinical/demographic data

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No